IL23A and Crohn disease: The current availability of the specific anti-p40 antibody ustekinumab and the expected arrival of specific anti-p19 antibodies broaden our therapeutic armamentarium in the treatment of Crohn’s disease, but inevitably leads us to the questions which patients would likely benefit the most from these compounds.